TVTX logo

TVTX Travere Therapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$48.30
-1.94 (-3.86%)

Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to s…

Market Cap: $4.64Bwww.travere.com

Price

No data yet.

Social Signal Score

58
5d
—
30d
58
12 mentions
—
60d
58
13 mentions
—
90d
57
16 mentions
—
news: 11 · marketaux: 1 · rss: 4

Analyst Ratings

18 analysts
Buyconsensus
Strong Buy 0Buy 15Hold 3Sell 0Strong Sell 0
Avg price target$76+57.3%
Low $67Median $74High $89
Current Consensus

Revenue

$224.56M+501.63%
$28.07M$93.57M$159.07M$224.56M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.34
$-0.69–$0.15
7 analysts
FY2026
$-0.79
$-0.90–$-0.63
8 analysts
FY2027
$3.00
$0.81–$5.06
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Eric Dube
Sector
Healthcare
Industry
Biotechnology
Employees
497
Beta
1.12
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
1.65
www.travere.com